Printer Friendly

GAMMA BIOLOGICALS NAMES JOHN J. MOULDS PRESIDENT

 GAMMA BIOLOGICALS NAMES JOHN J. MOULDS PRESIDENT
 HOUSTON, June 9 /PRNewswire/ -- The Gamma Biologicals, Inc.


(AMEX: GBL) board of directors announced today that it has appointed John J. Moulds president and chief operating officer. Previously, he was executive vice president and COO. David E. Hatcher remains chairman and chief executive officer.
 Moulds joined Gamma in 1975 as director of consultation & education and was named COO in 1988. Currently, he manages both the monoclonal reagent and bioelectrical sensor programs.
 Moulds earned a BA in biology and chemistry from Chadron State College, Chadron, Neb., and a medical technology (MT) degree from St. John's Hospital, Rapid City, S.D. He received his specialist in blood banking (SBB) from War Memorial Blood Bank, Minneapolis, in 1969, and he served as director of the consultation service there until joining Gamma.
 Well recognized within the profession, he has served as chairman of the International Society of Blood Transfusion's (ISBT) Committee for Blood Group Nomenclature and chairman of the rare donor file of the American Association of Blood Banks (AABB). Moulds founded the International Exchange of Rare Blood Specimens.
 Gamma Biologicals manufactures and markets a wide range of highly refined and specialized testing products, known as diagnostic reagents, as well as sophisticated instrument systems. The company markets to hospitals, blood banks, medical laboratories, physicians' offices and research institutions.
 -0- 6/9/92
 /CONTACT: David E. Hatcher, chairman of Gamma Biologicals, 713-660-7990/
 (GBL) CO: Gamma Biologicals, Inc. ST: Texas IN: MTC SU: PER


TS -- NY042 -- 8379 06/09/92 12:36 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 9, 1992
Words:254
Previous Article:TRACOR RECEIVES $8.2 MILLION NAVY CONTRACT
Next Article:LOGICON AWARDED CONTRACT FOR MILSTAR INDEPENDENT SECURITY VALIDATION AND VERIFICATION SUPPORT
Topics:


Related Articles
FINAL CASH SETTLEMENT ON ITALIAN SALE TO FUND BIOELECTRICAL SENSOR TECHNOLOGY DEVELOPMENT FOR GAMMA BIOLOGICALS
ANOTHER FIRST FOR GAMMA BIOLOGICALS; COMPANY RECEIVES FIRST EVER LICENSE FOR MONOCLONAL COOMBS REAGENTS
GAMMA BIOLOGICALS REVIEWS ELECTRO-BIOSENSOR PROJECT; TESTS CONFIRM PROJECT FEASIBILITY; DEVELOPMENT TO CONTINUE
GAMMA BIOLOGICALS REPORTS STRONG EARNINGS FOR QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 1993
GAMMA BIOLOGICALS REPORTS EARNINGS FOR FIRST QUARTER ENDED JUNE 30, 1994
GAMMA BIOLOGICALS ANNOUNCES DIVIDEND
GAMMA BIOLOGICALS ANNOUNCES JANUARY DIVIDEND
GAMMA BIOLOGICALS REPORTS EARNINGS FOR THIRD QUARTER AND NINE MONTHS ENDED DEC. 31, 1995
GAMMA BIOLOGICALS ANNOUNCES JULY DIVIDEND
Gamma Biologicals Reports Earnings for the Third Quarter and Nine Months Ended December 31, 1996

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters